Navigation Links
Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
Date:11/8/2013

KANSAS CITY, Kan., Nov. 8, 2013 /PRNewswire/ -- Stason Pharmaceuticals, Inc. announced today that it is expanding into Kansas City by moving its brand division from Irvine, Calif. to Kansas City, Kan.  A new entity has been developed, KC Specialty Therapeutics LLC, in which the new assets will be placed to focus on research and development of new chemical entities for humans.

"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."

Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.

KC Specialty Therapeutics LLC will locate alongside Stason Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus.  Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.

"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, president and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."

About Stason Pharmaceuticals
Stason Pharmaceuticals entered the commercial generic market in 1994 and today continues to manufacture and market these products through a global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies, and in 2008, Stason launched its Brand Division. Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. http://www.stasonpharma.com/

About KC Specialty Therapeutics LLC
KC Specialty Pharma is focused on the development of new chemical entities in human orphan drug indications for which there is no available treatment.  Orphan drugs are defined as those that treat less than 200,000 in the US. 

About Greater Kansas City
Home to 2.5 million people, the Kansas City region offers the benefits of more than 50 unique communities and 18 counties in Kansas and Missouri.  www.thinkKC.com


'/>"/>
SOURCE Kansas City Area Development Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
4. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
6. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
7. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
8. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
9. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... FALLS, N.J. , March 22, 2017  CANTEL MEDICAL ... Jorgen B. Hansen , President and CEO, will be presenting ... Conference at the Westin Grand Central Hotel in ... Wednesday, April 5, 2017 at 3:00 p.m. ET. In addition, ... day. A live audio webcast will be ...
(Date:3/22/2017)... JACKSONVILLE, Fla. , March 22, 2017 /PRNewswire/ ... clinical-stage immuno-oncology company specializing in the development of ... of cancer and metastatic disease, today announced that ... Industry conferences. Dr. Glynn Wilson ... an overview of the company,s business, clinical pipeline ...
(Date:3/22/2017)... 22, 2017 Hologic, Inc. (Nasdaq: ... acquisition of Cynosure, Inc., a leader in medical aesthetics ... "We are pleased to complete our acquisition ... Michael Davin and the entire Cynosure team to ... medical aesthetics market," said Steve MacMillan , Hologic,s ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam & Associates Insurance Agency, ... and related services to residents of the region, is embarking on a charity ... and wild lands. , Endangered Species International is committed to ending the anthropogenic ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... FL (PRWEB) , ... March 22, 2017 , ... An ... mosquitoes could occasionally transmit HIV, reports Leslie Norins, MD, PhD. He says ... cases of domestically transmitted Zika virus and in new infections with HIV. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Oklahoma City, OK (PRWEB) , ... March 22, ... ... firm offering insurance and financial planning services to regional families and business owners, ... provide meaningful support to young people in the area. , A growing number ...
Breaking Medicine News(10 mins):